Research ArticleArticle
Determining Best Practices in Early Rheumatoid Arthritis by Comparing Differences in Treatment at Sites in the Canadian Early Arthritis Cohort
Jamie A. Harris, Vivian P. Bykerk, Carol A. Hitchon, E.C. Keystone, J. Carter Thorne, Gilles Boire, Boulos Haraoui, Glen Hazlewood, Ashley J. Bonner and Janet E. Pope on behalf of the CATCH Investigators
The Journal of Rheumatology September 2013, jrheum.121316; DOI: https://doi.org/10.3899/jrheum.121316
Jamie A. Harris
From the Rheumatology Centre, St. Joseph’s Health Care, London, Ontario, Canada; the Hospital for Special Surgery, New York, New York, USA; the Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; the University of Toronto, Toronto; Southlake Regional Health Centre, Newmarket, Ontario; the Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke, Sherbrooke, Quebec; the Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; McMaster University, Hamilton, Ontario; and Western University, London, Ontario, Canada. The Canadian Early Arthritis Cohort (CATCH) study was supported initially by Amgen Canada Inc. and Pfizer Canada Inc. through an unrestricted research grant. As of 2011, further support was provided by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., Abbott Laboratories Ltd., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). The study was designed and implemented by the investigators. Jamie Harris received The Arthritis Society/Canadian Arthritis Network Summer Research Program for Medical and Allied Health Professionals Studentship and a JuMP (Joint Motion Program) Summer Trainee Studentship (Canadian Institutes of Health Research NET training grant). J.A. Harris, BScN (candidate), Western University; V.P. Bykerk, MD, FRCPC, Hospital for Special Surgery Inflammatory Arthritis Center; C.A. Hitchon, MD, Arthritis Centre, Associate Professor of Medicine, University of Manitoba; E.C. Keystone, MD, FRCPC, Professor of Medicine, University of Toronto, Director, Rebecca MacDonald Centre for Arthritis and Autoimmune Disease; J.C. Thorne, MD, FCRP, FACP, Chief of the Division of Rheumatology, Director of the Arthritis Program, Southlake Regional Health Centre; G. Boire, MD, MSc, Professor, Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke; B. Haraoui, MD, FRCPC, Rheumatic Disease Unit, Institut de Rhumatologie, Associate Professor of Medicine, Université de Montréal; G. Hazlewood, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto; A.J. Bonner, MSc, PhD (candidate), McMaster University; J.E. Pope, MD, MPH, FRCPC, Chief of the Rheumatology Centre, St. Joseph’s Health Care, Professor, Department of Medicine, Division of Rheumatology, Western University. Address correspondence to Dr. J. Pope, St. Joseph’s Health Care, 268 Grosvenor St., London, Ontario N6A 4V2, Canada. E-mail: Janet.Pope@sjhc.london.on.ca Accepted for publication July 19, 2013.
Vivian P. Bykerk
From the Rheumatology Centre, St. Joseph’s Health Care, London, Ontario, Canada; the Hospital for Special Surgery, New York, New York, USA; the Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; the University of Toronto, Toronto; Southlake Regional Health Centre, Newmarket, Ontario; the Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke, Sherbrooke, Quebec; the Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; McMaster University, Hamilton, Ontario; and Western University, London, Ontario, Canada. The Canadian Early Arthritis Cohort (CATCH) study was supported initially by Amgen Canada Inc. and Pfizer Canada Inc. through an unrestricted research grant. As of 2011, further support was provided by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., Abbott Laboratories Ltd., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). The study was designed and implemented by the investigators. Jamie Harris received The Arthritis Society/Canadian Arthritis Network Summer Research Program for Medical and Allied Health Professionals Studentship and a JuMP (Joint Motion Program) Summer Trainee Studentship (Canadian Institutes of Health Research NET training grant). J.A. Harris, BScN (candidate), Western University; V.P. Bykerk, MD, FRCPC, Hospital for Special Surgery Inflammatory Arthritis Center; C.A. Hitchon, MD, Arthritis Centre, Associate Professor of Medicine, University of Manitoba; E.C. Keystone, MD, FRCPC, Professor of Medicine, University of Toronto, Director, Rebecca MacDonald Centre for Arthritis and Autoimmune Disease; J.C. Thorne, MD, FCRP, FACP, Chief of the Division of Rheumatology, Director of the Arthritis Program, Southlake Regional Health Centre; G. Boire, MD, MSc, Professor, Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke; B. Haraoui, MD, FRCPC, Rheumatic Disease Unit, Institut de Rhumatologie, Associate Professor of Medicine, Université de Montréal; G. Hazlewood, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto; A.J. Bonner, MSc, PhD (candidate), McMaster University; J.E. Pope, MD, MPH, FRCPC, Chief of the Rheumatology Centre, St. Joseph’s Health Care, Professor, Department of Medicine, Division of Rheumatology, Western University. Address correspondence to Dr. J. Pope, St. Joseph’s Health Care, 268 Grosvenor St., London, Ontario N6A 4V2, Canada. E-mail: Janet.Pope@sjhc.london.on.ca Accepted for publication July 19, 2013.
Carol A. Hitchon
From the Rheumatology Centre, St. Joseph’s Health Care, London, Ontario, Canada; the Hospital for Special Surgery, New York, New York, USA; the Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; the University of Toronto, Toronto; Southlake Regional Health Centre, Newmarket, Ontario; the Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke, Sherbrooke, Quebec; the Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; McMaster University, Hamilton, Ontario; and Western University, London, Ontario, Canada. The Canadian Early Arthritis Cohort (CATCH) study was supported initially by Amgen Canada Inc. and Pfizer Canada Inc. through an unrestricted research grant. As of 2011, further support was provided by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., Abbott Laboratories Ltd., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). The study was designed and implemented by the investigators. Jamie Harris received The Arthritis Society/Canadian Arthritis Network Summer Research Program for Medical and Allied Health Professionals Studentship and a JuMP (Joint Motion Program) Summer Trainee Studentship (Canadian Institutes of Health Research NET training grant). J.A. Harris, BScN (candidate), Western University; V.P. Bykerk, MD, FRCPC, Hospital for Special Surgery Inflammatory Arthritis Center; C.A. Hitchon, MD, Arthritis Centre, Associate Professor of Medicine, University of Manitoba; E.C. Keystone, MD, FRCPC, Professor of Medicine, University of Toronto, Director, Rebecca MacDonald Centre for Arthritis and Autoimmune Disease; J.C. Thorne, MD, FCRP, FACP, Chief of the Division of Rheumatology, Director of the Arthritis Program, Southlake Regional Health Centre; G. Boire, MD, MSc, Professor, Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke; B. Haraoui, MD, FRCPC, Rheumatic Disease Unit, Institut de Rhumatologie, Associate Professor of Medicine, Université de Montréal; G. Hazlewood, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto; A.J. Bonner, MSc, PhD (candidate), McMaster University; J.E. Pope, MD, MPH, FRCPC, Chief of the Rheumatology Centre, St. Joseph’s Health Care, Professor, Department of Medicine, Division of Rheumatology, Western University. Address correspondence to Dr. J. Pope, St. Joseph’s Health Care, 268 Grosvenor St., London, Ontario N6A 4V2, Canada. E-mail: Janet.Pope@sjhc.london.on.ca Accepted for publication July 19, 2013.
E.C. Keystone
From the Rheumatology Centre, St. Joseph’s Health Care, London, Ontario, Canada; the Hospital for Special Surgery, New York, New York, USA; the Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; the University of Toronto, Toronto; Southlake Regional Health Centre, Newmarket, Ontario; the Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke, Sherbrooke, Quebec; the Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; McMaster University, Hamilton, Ontario; and Western University, London, Ontario, Canada. The Canadian Early Arthritis Cohort (CATCH) study was supported initially by Amgen Canada Inc. and Pfizer Canada Inc. through an unrestricted research grant. As of 2011, further support was provided by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., Abbott Laboratories Ltd., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). The study was designed and implemented by the investigators. Jamie Harris received The Arthritis Society/Canadian Arthritis Network Summer Research Program for Medical and Allied Health Professionals Studentship and a JuMP (Joint Motion Program) Summer Trainee Studentship (Canadian Institutes of Health Research NET training grant). J.A. Harris, BScN (candidate), Western University; V.P. Bykerk, MD, FRCPC, Hospital for Special Surgery Inflammatory Arthritis Center; C.A. Hitchon, MD, Arthritis Centre, Associate Professor of Medicine, University of Manitoba; E.C. Keystone, MD, FRCPC, Professor of Medicine, University of Toronto, Director, Rebecca MacDonald Centre for Arthritis and Autoimmune Disease; J.C. Thorne, MD, FCRP, FACP, Chief of the Division of Rheumatology, Director of the Arthritis Program, Southlake Regional Health Centre; G. Boire, MD, MSc, Professor, Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke; B. Haraoui, MD, FRCPC, Rheumatic Disease Unit, Institut de Rhumatologie, Associate Professor of Medicine, Université de Montréal; G. Hazlewood, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto; A.J. Bonner, MSc, PhD (candidate), McMaster University; J.E. Pope, MD, MPH, FRCPC, Chief of the Rheumatology Centre, St. Joseph’s Health Care, Professor, Department of Medicine, Division of Rheumatology, Western University. Address correspondence to Dr. J. Pope, St. Joseph’s Health Care, 268 Grosvenor St., London, Ontario N6A 4V2, Canada. E-mail: Janet.Pope@sjhc.london.on.ca Accepted for publication July 19, 2013.
J. Carter Thorne
From the Rheumatology Centre, St. Joseph’s Health Care, London, Ontario, Canada; the Hospital for Special Surgery, New York, New York, USA; the Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; the University of Toronto, Toronto; Southlake Regional Health Centre, Newmarket, Ontario; the Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke, Sherbrooke, Quebec; the Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; McMaster University, Hamilton, Ontario; and Western University, London, Ontario, Canada. The Canadian Early Arthritis Cohort (CATCH) study was supported initially by Amgen Canada Inc. and Pfizer Canada Inc. through an unrestricted research grant. As of 2011, further support was provided by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., Abbott Laboratories Ltd., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). The study was designed and implemented by the investigators. Jamie Harris received The Arthritis Society/Canadian Arthritis Network Summer Research Program for Medical and Allied Health Professionals Studentship and a JuMP (Joint Motion Program) Summer Trainee Studentship (Canadian Institutes of Health Research NET training grant). J.A. Harris, BScN (candidate), Western University; V.P. Bykerk, MD, FRCPC, Hospital for Special Surgery Inflammatory Arthritis Center; C.A. Hitchon, MD, Arthritis Centre, Associate Professor of Medicine, University of Manitoba; E.C. Keystone, MD, FRCPC, Professor of Medicine, University of Toronto, Director, Rebecca MacDonald Centre for Arthritis and Autoimmune Disease; J.C. Thorne, MD, FCRP, FACP, Chief of the Division of Rheumatology, Director of the Arthritis Program, Southlake Regional Health Centre; G. Boire, MD, MSc, Professor, Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke; B. Haraoui, MD, FRCPC, Rheumatic Disease Unit, Institut de Rhumatologie, Associate Professor of Medicine, Université de Montréal; G. Hazlewood, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto; A.J. Bonner, MSc, PhD (candidate), McMaster University; J.E. Pope, MD, MPH, FRCPC, Chief of the Rheumatology Centre, St. Joseph’s Health Care, Professor, Department of Medicine, Division of Rheumatology, Western University. Address correspondence to Dr. J. Pope, St. Joseph’s Health Care, 268 Grosvenor St., London, Ontario N6A 4V2, Canada. E-mail: Janet.Pope@sjhc.london.on.ca Accepted for publication July 19, 2013.
Gilles Boire
From the Rheumatology Centre, St. Joseph’s Health Care, London, Ontario, Canada; the Hospital for Special Surgery, New York, New York, USA; the Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; the University of Toronto, Toronto; Southlake Regional Health Centre, Newmarket, Ontario; the Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke, Sherbrooke, Quebec; the Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; McMaster University, Hamilton, Ontario; and Western University, London, Ontario, Canada. The Canadian Early Arthritis Cohort (CATCH) study was supported initially by Amgen Canada Inc. and Pfizer Canada Inc. through an unrestricted research grant. As of 2011, further support was provided by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., Abbott Laboratories Ltd., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). The study was designed and implemented by the investigators. Jamie Harris received The Arthritis Society/Canadian Arthritis Network Summer Research Program for Medical and Allied Health Professionals Studentship and a JuMP (Joint Motion Program) Summer Trainee Studentship (Canadian Institutes of Health Research NET training grant). J.A. Harris, BScN (candidate), Western University; V.P. Bykerk, MD, FRCPC, Hospital for Special Surgery Inflammatory Arthritis Center; C.A. Hitchon, MD, Arthritis Centre, Associate Professor of Medicine, University of Manitoba; E.C. Keystone, MD, FRCPC, Professor of Medicine, University of Toronto, Director, Rebecca MacDonald Centre for Arthritis and Autoimmune Disease; J.C. Thorne, MD, FCRP, FACP, Chief of the Division of Rheumatology, Director of the Arthritis Program, Southlake Regional Health Centre; G. Boire, MD, MSc, Professor, Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke; B. Haraoui, MD, FRCPC, Rheumatic Disease Unit, Institut de Rhumatologie, Associate Professor of Medicine, Université de Montréal; G. Hazlewood, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto; A.J. Bonner, MSc, PhD (candidate), McMaster University; J.E. Pope, MD, MPH, FRCPC, Chief of the Rheumatology Centre, St. Joseph’s Health Care, Professor, Department of Medicine, Division of Rheumatology, Western University. Address correspondence to Dr. J. Pope, St. Joseph’s Health Care, 268 Grosvenor St., London, Ontario N6A 4V2, Canada. E-mail: Janet.Pope@sjhc.london.on.ca Accepted for publication July 19, 2013.
Boulos Haraoui
From the Rheumatology Centre, St. Joseph’s Health Care, London, Ontario, Canada; the Hospital for Special Surgery, New York, New York, USA; the Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; the University of Toronto, Toronto; Southlake Regional Health Centre, Newmarket, Ontario; the Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke, Sherbrooke, Quebec; the Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; McMaster University, Hamilton, Ontario; and Western University, London, Ontario, Canada. The Canadian Early Arthritis Cohort (CATCH) study was supported initially by Amgen Canada Inc. and Pfizer Canada Inc. through an unrestricted research grant. As of 2011, further support was provided by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., Abbott Laboratories Ltd., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). The study was designed and implemented by the investigators. Jamie Harris received The Arthritis Society/Canadian Arthritis Network Summer Research Program for Medical and Allied Health Professionals Studentship and a JuMP (Joint Motion Program) Summer Trainee Studentship (Canadian Institutes of Health Research NET training grant). J.A. Harris, BScN (candidate), Western University; V.P. Bykerk, MD, FRCPC, Hospital for Special Surgery Inflammatory Arthritis Center; C.A. Hitchon, MD, Arthritis Centre, Associate Professor of Medicine, University of Manitoba; E.C. Keystone, MD, FRCPC, Professor of Medicine, University of Toronto, Director, Rebecca MacDonald Centre for Arthritis and Autoimmune Disease; J.C. Thorne, MD, FCRP, FACP, Chief of the Division of Rheumatology, Director of the Arthritis Program, Southlake Regional Health Centre; G. Boire, MD, MSc, Professor, Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke; B. Haraoui, MD, FRCPC, Rheumatic Disease Unit, Institut de Rhumatologie, Associate Professor of Medicine, Université de Montréal; G. Hazlewood, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto; A.J. Bonner, MSc, PhD (candidate), McMaster University; J.E. Pope, MD, MPH, FRCPC, Chief of the Rheumatology Centre, St. Joseph’s Health Care, Professor, Department of Medicine, Division of Rheumatology, Western University. Address correspondence to Dr. J. Pope, St. Joseph’s Health Care, 268 Grosvenor St., London, Ontario N6A 4V2, Canada. E-mail: Janet.Pope@sjhc.london.on.ca Accepted for publication July 19, 2013.
Glen Hazlewood
From the Rheumatology Centre, St. Joseph’s Health Care, London, Ontario, Canada; the Hospital for Special Surgery, New York, New York, USA; the Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; the University of Toronto, Toronto; Southlake Regional Health Centre, Newmarket, Ontario; the Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke, Sherbrooke, Quebec; the Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; McMaster University, Hamilton, Ontario; and Western University, London, Ontario, Canada. The Canadian Early Arthritis Cohort (CATCH) study was supported initially by Amgen Canada Inc. and Pfizer Canada Inc. through an unrestricted research grant. As of 2011, further support was provided by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., Abbott Laboratories Ltd., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). The study was designed and implemented by the investigators. Jamie Harris received The Arthritis Society/Canadian Arthritis Network Summer Research Program for Medical and Allied Health Professionals Studentship and a JuMP (Joint Motion Program) Summer Trainee Studentship (Canadian Institutes of Health Research NET training grant). J.A. Harris, BScN (candidate), Western University; V.P. Bykerk, MD, FRCPC, Hospital for Special Surgery Inflammatory Arthritis Center; C.A. Hitchon, MD, Arthritis Centre, Associate Professor of Medicine, University of Manitoba; E.C. Keystone, MD, FRCPC, Professor of Medicine, University of Toronto, Director, Rebecca MacDonald Centre for Arthritis and Autoimmune Disease; J.C. Thorne, MD, FCRP, FACP, Chief of the Division of Rheumatology, Director of the Arthritis Program, Southlake Regional Health Centre; G. Boire, MD, MSc, Professor, Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke; B. Haraoui, MD, FRCPC, Rheumatic Disease Unit, Institut de Rhumatologie, Associate Professor of Medicine, Université de Montréal; G. Hazlewood, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto; A.J. Bonner, MSc, PhD (candidate), McMaster University; J.E. Pope, MD, MPH, FRCPC, Chief of the Rheumatology Centre, St. Joseph’s Health Care, Professor, Department of Medicine, Division of Rheumatology, Western University. Address correspondence to Dr. J. Pope, St. Joseph’s Health Care, 268 Grosvenor St., London, Ontario N6A 4V2, Canada. E-mail: Janet.Pope@sjhc.london.on.ca Accepted for publication July 19, 2013.
Ashley J. Bonner
From the Rheumatology Centre, St. Joseph’s Health Care, London, Ontario, Canada; the Hospital for Special Surgery, New York, New York, USA; the Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; the University of Toronto, Toronto; Southlake Regional Health Centre, Newmarket, Ontario; the Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke, Sherbrooke, Quebec; the Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; McMaster University, Hamilton, Ontario; and Western University, London, Ontario, Canada. The Canadian Early Arthritis Cohort (CATCH) study was supported initially by Amgen Canada Inc. and Pfizer Canada Inc. through an unrestricted research grant. As of 2011, further support was provided by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., Abbott Laboratories Ltd., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). The study was designed and implemented by the investigators. Jamie Harris received The Arthritis Society/Canadian Arthritis Network Summer Research Program for Medical and Allied Health Professionals Studentship and a JuMP (Joint Motion Program) Summer Trainee Studentship (Canadian Institutes of Health Research NET training grant). J.A. Harris, BScN (candidate), Western University; V.P. Bykerk, MD, FRCPC, Hospital for Special Surgery Inflammatory Arthritis Center; C.A. Hitchon, MD, Arthritis Centre, Associate Professor of Medicine, University of Manitoba; E.C. Keystone, MD, FRCPC, Professor of Medicine, University of Toronto, Director, Rebecca MacDonald Centre for Arthritis and Autoimmune Disease; J.C. Thorne, MD, FCRP, FACP, Chief of the Division of Rheumatology, Director of the Arthritis Program, Southlake Regional Health Centre; G. Boire, MD, MSc, Professor, Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke; B. Haraoui, MD, FRCPC, Rheumatic Disease Unit, Institut de Rhumatologie, Associate Professor of Medicine, Université de Montréal; G. Hazlewood, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto; A.J. Bonner, MSc, PhD (candidate), McMaster University; J.E. Pope, MD, MPH, FRCPC, Chief of the Rheumatology Centre, St. Joseph’s Health Care, Professor, Department of Medicine, Division of Rheumatology, Western University. Address correspondence to Dr. J. Pope, St. Joseph’s Health Care, 268 Grosvenor St., London, Ontario N6A 4V2, Canada. E-mail: Janet.Pope@sjhc.london.on.ca Accepted for publication July 19, 2013.
Janet E. Pope
From the Rheumatology Centre, St. Joseph’s Health Care, London, Ontario, Canada; the Hospital for Special Surgery, New York, New York, USA; the Arthritis Centre, University of Manitoba, Winnipeg, Manitoba; the University of Toronto, Toronto; Southlake Regional Health Centre, Newmarket, Ontario; the Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke, Sherbrooke, Quebec; the Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; McMaster University, Hamilton, Ontario; and Western University, London, Ontario, Canada. The Canadian Early Arthritis Cohort (CATCH) study was supported initially by Amgen Canada Inc. and Pfizer Canada Inc. through an unrestricted research grant. As of 2011, further support was provided by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., Abbott Laboratories Ltd., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). The study was designed and implemented by the investigators. Jamie Harris received The Arthritis Society/Canadian Arthritis Network Summer Research Program for Medical and Allied Health Professionals Studentship and a JuMP (Joint Motion Program) Summer Trainee Studentship (Canadian Institutes of Health Research NET training grant). J.A. Harris, BScN (candidate), Western University; V.P. Bykerk, MD, FRCPC, Hospital for Special Surgery Inflammatory Arthritis Center; C.A. Hitchon, MD, Arthritis Centre, Associate Professor of Medicine, University of Manitoba; E.C. Keystone, MD, FRCPC, Professor of Medicine, University of Toronto, Director, Rebecca MacDonald Centre for Arthritis and Autoimmune Disease; J.C. Thorne, MD, FCRP, FACP, Chief of the Division of Rheumatology, Director of the Arthritis Program, Southlake Regional Health Centre; G. Boire, MD, MSc, Professor, Faculty of Medicine and Health Sciences, Division of Rheumatology, Université de Sherbrooke; B. Haraoui, MD, FRCPC, Rheumatic Disease Unit, Institut de Rhumatologie, Associate Professor of Medicine, Université de Montréal; G. Hazlewood, MD, FRCPC, Department of Rheumatology, Mount Sinai Hospital, University of Toronto; A.J. Bonner, MSc, PhD (candidate), McMaster University; J.E. Pope, MD, MPH, FRCPC, Chief of the Rheumatology Centre, St. Joseph’s Health Care, Professor, Department of Medicine, Division of Rheumatology, Western University. Address correspondence to Dr. J. Pope, St. Joseph’s Health Care, 268 Grosvenor St., London, Ontario N6A 4V2, Canada. E-mail: Janet.Pope@sjhc.london.on.ca Accepted for publication July 19, 2013.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Determining Best Practices in Early Rheumatoid Arthritis by Comparing Differences in Treatment at Sites in the Canadian Early Arthritis Cohort
Jamie A. Harris, Vivian P. Bykerk, Carol A. Hitchon, E.C. Keystone, J. Carter Thorne, Gilles Boire, Boulos Haraoui, Glen Hazlewood, Ashley J. Bonner, Janet E. Pope
The Journal of Rheumatology Sep 2013, jrheum.121316; DOI: 10.3899/jrheum.121316
Determining Best Practices in Early Rheumatoid Arthritis by Comparing Differences in Treatment at Sites in the Canadian Early Arthritis Cohort
Jamie A. Harris, Vivian P. Bykerk, Carol A. Hitchon, E.C. Keystone, J. Carter Thorne, Gilles Boire, Boulos Haraoui, Glen Hazlewood, Ashley J. Bonner, Janet E. Pope
The Journal of Rheumatology Sep 2013, jrheum.121316; DOI: 10.3899/jrheum.121316